GlassScriptPhysician profile
Jenna D Peterman
NPI 1942882972
$2,948.77
in general payments reported to CMS, 2019-2025
30 companies · $390 in 2025
The $390 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $475 · 2022: $830 · 2023: $645 · 2024: $610 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,644.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $722.49 | 2021-2025 | |
| Alcon Vision LLC | $367.38 | 2023-2025 | Rocklatan |
| Sun Pharmaceutical Industries INC. | $232.92 | 2023-2024 | Cequa |
| Bausch & Lomb Americas INC. | $201.28 | 2024-2025 | Miebo, Vyzulta, Xiidra |
| Janssen Pharmaceuticals, INC | $144.39 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $131.66 | 2022-2023 | |
| Lilly USA, LLC | $128.03 | 2021-2022 | |
| Novo Nordisk INC | $121.39 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $100.88 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $99.69 | 2021 | |
| Amgen INC. | $91.41 | 2021-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $81.27 | 2023 | Tecnis Simplicity |
| Bayer Healthcare Pharmaceuticals INC. | $58.54 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $52.10 | 2022 | |
| Sanofi-Aventis U.S. LLC | $47.28 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $42.10 | 2022 | |
| Mallinckrodt Hospital Products INC. | $37.97 | 2024 | Acthar |
| Harrow Eye, LLC | $32.15 | 2024 | Natacyn, Flarex, Verkazia |
| Cranial Technologies, INC | $30.07 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $29.25 | 2021 | |
| Glaukos Corporation | $25.59 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Apellis Pharmaceuticals, INC. | $24.99 | 2025 | Syfovre |
| Dompe US, INC. | $24.26 | 2024 | Oxervate |
| Xeris Pharmaceuticals, INC. | $22.16 | 2022 | |
| Merck Sharp & Dohme LLC | $21.57 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $21.31 | 2025 | Xdemvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.75 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.44 | 2022 | |
| Sanofi Pasteur INC. | $13.56 | 2021 | |
| Amarin Pharma, INC. | $12.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Peterman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.